Ventana rejects Roche takeover bid
This article was originally published in The Gray Sheet
Executive Summary
Tissue-based diagnostics firm Ventana rejects Roche's $3 billion hostile takeover bid as "inadequate" July 11. Roche, which hopes to pair the technology with its targeted cancer drugs for advanced personalized medicine, had announced the offer June 25. The diversified drug and diagnostics giant responded to Ventana's dismissal of the offer in a same-day letter, stating that if there is "additional information that would support a valuation in excess of our offer, we would be willing to consider it in a negotiation." Roche adds that if a negotiated transaction is not possible, it will continue with its $75-per-share cash tender offer, launched June 27, and consider taking the issue directly to Ventana's shareholders at the firm's 2008 annual meeting. "Such action may include the nomination of new directors to Ventana's board and/or proposals to amend Ventana's bylaws," Roche says (1"The Gray Sheet" July 2, 2007, p. 10)...
You may also be interested in...
Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid
Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.